Opportunity Information: Apply for CDC RFA IP11 1104
Apply for CDC RFA IP11 1104
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.283 Centers for Disease Control and PreventionInvestigations and Technical Assistance.
- This funding opportunity was created on Mar 24, 2011 and posted on Mar 24, 2011.
- Applicants must submit their applications by May 23, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $45,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,500,000.00 in funding.
- The number of recipients for this funding is limited to 6 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligible Applicants Eligible applicants that can apply for this funding opportunity are listed below Other Regional Offices of the World Health Organization. A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with Other Attachment Forms when submitting via www.grants.gov. WHO is a multi national organization that was established in April 1948 by diplomats of the United Nations. The United Nations appointed WHO as the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence based policy options, providing technical support to countries and monitoring and assessing health trends. WHO is known worldwide for its unique ability to work with countries around the world to provide leadership on matters critical to health and engage in partnerships where joint action is needed shape the research agenda and stimulate the generation, translation and dissemination of valuable knowledge set norms and standards and promote and monitor their implementation articulate ethical and evidence based policy options provide technical support, catalyst change, and build sustainable institutional capacity and monitor the health situation and assess health trends. WHO is the only organization that has the ability to fulfill the requirements of this announcement because of its authority to work globally with countries on health related issues. WHO has the ability to provide Member States with country level and regional support to build capacity for the identification, investigation and containment of a potential novel or pandemic strain of influenza lead regional surveillance and laboratory capacity building efforts develop and disseminate regional guidelines for surveillance and burden estimation and they have extensive knowledge of regional and country readiness to explore the development of vaccine policies. All of these activities are required for the successful completion of the announcement s requirements.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This grant opportunity, titled "Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization," was a CDC-funded cooperative agreement designed to strengthen how countries detect, track, and respond to influenza threats. The central aim was to support the six WHO Regional Offices in carrying out a coordinated plan that helps national governments and regional authorities improve influenza surveillance systems. The emphasis was not only on routine seasonal influenza monitoring, but also on building the capability to spot and contain novel influenza viruses with pandemic potential, including strains such as highly pathogenic avian influenza and swine-origin influenza viruses. In practical terms, the program sought to make influenza surveillance more consistent, more laboratory-confirmed, more epidemiologically useful, and more actionable for public health response.
A major focus of the funding was capacity-building in both laboratory and epidemiologic surveillance. On the laboratory side, the intent was to enhance the ability of countries to collect, test, and characterize influenza specimens so they can reliably identify circulating viruses and detect unusual or emerging strains early. On the epidemiology side, it targeted stronger systems for case detection, investigation, and data analysis so that surveillance information can guide decisions quickly during outbreaks. The opportunity also highlighted the need for simple and workable methods to estimate the burden of influenza disease. This meant encouraging approaches that use surveillance outputs together with other routinely collected health data to help countries and regions understand how much illness, hospitalization, and potentially death influenza causes, even in places where resources and data systems may be limited.
Beyond detection, the grant was explicitly tied to response readiness. The CDC sought to enable WHO Regional Offices to help Member States move toward routine identification, investigation, and containment of novel influenza viruses. That includes supporting outbreak detection and response for viruses that could trigger wider regional spread or a global pandemic. The WHO Regional Offices were positioned as the operational hub for this work because they can provide hands-on regional and country support, coordinate across multiple nations, and develop and disseminate regional guidance that standardizes surveillance practices and burden estimation methods.
Another important piece of the program involved policy support related to influenza vaccination. The opportunity aimed to assist countries in conducting activities that inform decisions about whether and how to introduce influenza vaccines, and how to increase vaccine use where appropriate. This reflects the idea that better surveillance and burden estimates are not just technical exercises; they are also the evidence base countries need to justify vaccine policy, target risk groups, and plan sustainable immunization strategies.
Administratively, this was a discretionary funding opportunity offered by the Centers for Disease Control and Prevention under CFDA 93.283 (Investigations and Technical Assistance). The funding instrument was a cooperative agreement, signaling that CDC expected substantial involvement and collaboration during implementation rather than a fully hands-off grant. The opportunity anticipated six awards, aligning with the six WHO Regional Offices, and listed an estimated total funding amount of $45,000,000. The award ceiling was $1,500,000 per award, with no cost sharing or matching requirement. The opportunity was posted March 24, 2011, and closed May 23, 2011, later archived June 22, 2011.
Eligibility was narrowly defined. The eligible applicants were the WHO Regional Offices, reflecting the rationale given in the announcement that WHO is uniquely positioned to fulfill the requirements because of its formal mandate, global authority, and established relationships with Member States. The description emphasizes WHO's role in setting norms and standards, providing technical support, monitoring health trends, shaping research agendas, and helping build sustainable capacity, all of which were considered necessary to deliver the program outcomes. The notice also references the concept of a bona fide agent where applicable, requiring documentation if an entity applies on behalf of a state or local government, though the primary eligible applicants remained WHO Regional Offices.
For technical issues accessing the full announcement, the contact listed was the CDC Procurement and Grants Office (TIMS) at 770-488-2700 and PGOTIM@cdc.gov.
FAQs: Surveillance and Response to Seasonal and Pandemic Influenza by WHO Regional Offices (CDC Cooperative Agreement)
What is the title of this grant opportunity?
The opportunity is titled "Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization."
What type of funding opportunity was this?
This was a CDC-funded cooperative agreement offered as discretionary funding under CFDA 93.283 (Investigations and Technical Assistance).
What was the main purpose of the cooperative agreement?
The central aim was to strengthen how countries detect, track, and respond to influenza threats by supporting the six WHO Regional Offices in carrying out a coordinated plan to improve influenza surveillance systems across Member States.
Was the focus only on seasonal influenza?
No. While routine seasonal influenza monitoring was a key emphasis, the opportunity also focused on building the ability to detect and contain novel influenza viruses with pandemic potential, including highly pathogenic avian influenza and swine-origin influenza viruses.
Why were WHO Regional Offices central to this program?
The WHO Regional Offices were positioned as the operational hub because they can provide hands-on regional and country support, coordinate activities across multiple nations, and develop and disseminate regional guidance to standardize surveillance practices and disease burden estimation methods.
How many awards were anticipated and why?
Six awards were anticipated, aligning with the six WHO Regional Offices.
What was the estimated total funding amount?
The opportunity listed an estimated total funding amount of $45,000,000.
What was the award ceiling per award?
The award ceiling was $1,500,000 per award.
Was cost sharing or matching required?
No. The opportunity stated there was no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility was narrowly defined: the eligible applicants were the WHO Regional Offices.
Could other organizations apply, such as universities, NGOs, or ministries of health?
Based on the information provided, eligibility was limited to WHO Regional Offices. The announcement rationale emphasized WHO's unique mandate, authority, and relationships with Member States as the basis for this narrow eligibility.
What does it mean that the instrument was a cooperative agreement?
A cooperative agreement indicates CDC expected substantial involvement and collaboration during implementation, rather than providing a fully hands-off grant.
What were the main technical areas the funding aimed to strengthen?
The opportunity emphasized capacity-building in both laboratory surveillance and epidemiologic surveillance, with the goal of making influenza surveillance more consistent, more laboratory-confirmed, more epidemiologically useful, and more actionable for public health response.
What laboratory surveillance improvements were emphasized?
The intent was to enhance countries' ability to collect, test, and characterize influenza specimens so they can reliably identify circulating viruses and detect unusual or emerging strains early.
What epidemiologic surveillance improvements were emphasized?
The opportunity targeted stronger systems for case detection, case investigation, and data analysis so that surveillance information can guide decisions quickly during outbreaks.
Did the program include measuring the burden of influenza disease?
Yes. The opportunity highlighted the need for simple and workable methods to estimate influenza disease burden, including approaches that combine surveillance outputs with other routinely collected health data to better understand illness, hospitalization, and potentially death due to influenza, even in resource-limited settings.
How was this funding tied to outbreak response readiness?
The program was explicitly linked to response readiness by enabling WHO Regional Offices to help Member States move toward routine identification, investigation, and containment of novel influenza viruses, including support for outbreak detection and response for viruses that could trigger regional spread or a global pandemic.
Did the opportunity address influenza vaccination policy?
Yes. It aimed to assist countries in conducting activities that inform decisions about whether and how to introduce influenza vaccines, and how to increase vaccine use where appropriate. The description connects better surveillance and burden estimates to the evidence base needed for vaccine policy and immunization planning.
What program outcomes was WHO considered uniquely positioned to deliver?
The notice emphasized WHO's formal mandate and role in setting norms and standards, providing technical support, monitoring health trends, shaping research agendas, and helping build sustainable capacity. These functions were described as necessary to deliver the intended surveillance, burden estimation, and response outcomes.
What is CFDA 93.283?
CFDA 93.283 was identified in the opportunity as "Investigations and Technical Assistance," under which this discretionary cooperative agreement was offered.
When was the opportunity posted and when did it close?
The opportunity was posted on March 24, 2011, and closed on May 23, 2011. It was later archived on June 22, 2011.
Who should be contacted for technical issues accessing the full announcement?
For technical issues accessing the full announcement, the contact listed was the CDC Procurement and Grants Office (TIMS) at 770-488-2700 and PGOTIM@cdc.gov.
What is meant by "bona fide agent" in the eligibility discussion?
The notice references the concept of a bona fide agent where applicable and indicates documentation would be required if an entity applies on behalf of a state or local government. However, the primary eligible applicants remained WHO Regional Offices based on the information provided.
What kinds of influenza threats were explicitly mentioned as priorities?
The description explicitly referenced novel influenza viruses with pandemic potential, including highly pathogenic avian influenza and swine-origin influenza viruses, alongside routine seasonal influenza surveillance.
What was the practical goal for surveillance data under this program?
The practical intent was for influenza surveillance to be more consistent across settings, more frequently laboratory-confirmed, more useful for epidemiologic interpretation, and more actionable for public health decision-making and response.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: Microscale Plasma Devices (MPD)
Previous opportunity: Health Careers Opportunity Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA IP11 1104
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA IP11 1104) also looked into and applied for these:
| Funding Opportunity |
|---|
| Evaluation of Core Violence and Injury Prevention Program (Core VIPP) Apply for CDC RFA CE11 1106 Funding Number: CDC RFA CE11 1106 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Integrated Health Social Marketing Apply for RFA674 11 27 Funding Number: RFA674 11 27 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $20,000,000 |
| Systems Approach to Immunity and Inflammation (U19) Apply for RFA AI 11 017 Funding Number: RFA AI 11 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Multidisciplinary Clinical Research Centers (P60) Apply for RFA AR 12 001 Funding Number: RFA AR 12 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Enhanced Comprehensive HIV Prevention Planning and Implementation for Metropolitan Statistical Areas Most Affected by HIV/AIDS Phase II Apply for CDC RFA PS11 1117 Funding Number: CDC RFA PS11 1117 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Integrated Economic, Dynamic Disease, Risk and Decision Analytic Modeling of Global and Domestic Policy Issues for Polio Apply for CDC RFA IP11 1102 Funding Number: CDC RFA IP11 1102 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Translation of Pluripotent Stem Cell Therapies for Blood Diseases (R01) Apply for PA 11 186 Funding Number: PA 11 186 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| A National Coalition to Enhance STD/HIV Prevention through Promotion of a Holistic Approach to Health and Wellness Apply for CDC RFA PS11 1112 Funding Number: CDC RFA PS11 1112 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $135,000 |
| Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (UM1) Apply for RFA AI 11 002 Funding Number: RFA AI 11 002 Agency: National Institutes of Health Category: Health Funding Amount: $19,000,000 |
| Initiatives to Educate State Officials and Policy Makers about Priority Public Health Issues Related to the Prevention and Control of Sexually Transmitted Diseases (STDs) and Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome ( Apply for CDC RFA PS11 1118 Funding Number: CDC RFA PS11 1118 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Eliminating Mother to Child HIV Transmission in the United States through Continuous Quality Improvement The FIMR HIV Prevention Methodology Apply for CDC RFA PS11 1116 Funding Number: CDC RFA PS11 1116 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| PPHF 2012 Immunization Capacity Building Assistance to Strengthen Public Health Immunization Infrastructure and Performance financed in part by 2012 Prevention and Public Health Funds Apply for CDC RFA IP11 1107PPHF11 Funding Number: CDC RFA IP11 1107PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Next Generation PrEP II (R01) Apply for RFA AI 11 023 Funding Number: RFA AI 11 023 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Cooperative Agreements for Screening, Brief Intervention and Referral to Treatment Apply for TI 11 005 Funding Number: TI 11 005 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $1,666,000 |
| Limited Competition for the Continuation of Rare Diseases Clinical Research Consortia in the Rare Diseases Clinical Research Network (U54) Apply for PAR 11 187 Funding Number: PAR 11 187 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Optimizing Fidelity of Empirically Supported Behavioral Treatments for Mental Disorders (R21/R33) Apply for RFA MH 12 050 Funding Number: RFA MH 12 050 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Strengthening Angolan Systems for Health (SASH) Apply for RFA674 11 32 Funding Number: RFA674 11 32 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $33,000,000 |
| Support of NIAMS Program Project Grants (P01) Apply for PAR 11 188 Funding Number: PAR 11 188 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Dental Reimbursement Program Apply for HRSA 11 097 Funding Number: HRSA 11 097 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Public Health Prevention Fund Streamlined Surveillance for Ventilator Associated Pneumonia Reducing Burden and Demonstrating Preventability Apply for CDC RFA CK11 0010101PPHF11 Funding Number: CDC RFA CK11 0010101PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,508,825 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA IP11 1104", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.